Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041293 | 0.84 | NAPRT (0.45) | LMNANAPRTALDH1A1 | |
| SCHEMBL4806628 | 0.77 | CYP3A4 (0.49) | KMT2ALMNAOPRK1ALDH1A1 | |
| SCHEMBL3696556 | 0.76 | DDB1 (0.49) | DDB1CRBN | |
| SCHEMBL3788196 | 0.76 | DDB1 (0.42) | LMNATDP1DDB1CRBNALDH1A1 | |
| SCHEMBL3789659 | 0.75 | DDB1 (0.46) | DDB1CRBN | |
| SCHEMBL3776600 | 0.75 | DDB1 (0.46) | KMT2ALMNATDP1DDB1CRBN | |
| SCHEMBL3781275 | 0.74 | CYP17A1 (0.49) | CYP17A1CYP19A1KMT2ALMNATDP1 | |
| SCHEMBL4809720 | 0.74 | TACR1 (0.55) | ALDH1A1 | |
| SCHEMBL16242486 | 0.74 | CYP3A4 (0.39) | KMT2ALMNADDB1CRBNALDH1A1 | |
| SCHEMBL28055381 | 0.72 | DDB1 (0.64) | KMT2ATDP1DDB1CRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309341-B2 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratories Server (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-12-30 | — | — | US | disclosed |
| CN-101928241-A | 2-mercaptopentancarboxacid acid derivatives, its preparation method and contain their medicinal compositions | SERVIER LAB | 2010-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | CYP2B6, CYP2A6, MC5R | CYP17A1 1179/4885CYP19A1 1554/4885KMT2A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.